[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline 2 July 2021]
We are inviting expressions of interest (EoI) for commercializing “Prediction of Colorectal Adenoma Recurrence” technology. The innovation is developed by Professor Siew Chien Ng, Professor of the Department of Medicine and Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 20/MED/983).
The Technology
Colorectal cancer (CRC) is one of the most common malignancies worldwide. It is common practice for post polypectomy patients to have follow-up colonoscopic surveillance examinations to detect adenoma recurrence at recommended intervals. The purpose of this invention is to define molecular tests targeting sensitive bacterial biomarkers to predict the recurrence of adenoma.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
